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In recent years, hops prenylflavonoids have been the subject of the research by many 
scientists because of the wide spectrum of their biological effects. They have been confirmed, 
among other things, as effective antiproliferative drugs for colorectal cancer cells. Oxaliplatin 
is an effective alkylating cytostatic, whose main indication is the treatment of colorectal cancer. 
However, using oxaliplatin in therapy of cancer is limited by its neurological toxicity. When 
used in combination with other drugs, as it is used in clinical practice, it is possible to reduce 
therapeutic dose without loss of effect. Current therapeutic regimens with oxaliplatin are not 
free from this neurological toxicity. It would be helpful to find a substance that would help 
reduce the dose while being as non-toxic as possible. The aim of this work is to evaluate the 
effect of xanthohumol, isoxanthohumol and oxaliplatin on SW620 colorectal carcinoma cells 
and study the impact of selected prenylflavonoids on the effect of oxaliplatin therapy in human 
colon adenocarcinoma cell line. The thesis also deals with determination of the mRNA 
expression changes of selected biotransformation enzymes (carbonylreductase 1, quinon 
reductase 1, sulfotransferase 1A1, glutathione-S-transferase and catechol-O-methyltransferase 
2) associated with cancer. The antiproliferative effect of xanthohumol and isoxanthohumol was 
confirmed. Synergistic effect of combination was not observed. Result of gene expression 
quantification demonstrated that isoxanthohumol decreased the expression of GSTP-1, while 
CBR1 expression was increased. According to this particular study, prenylflavonoids combined 
with oxaliplatin are not favorable for the combination therapy. 
 
